China Cancer Drug Market: Size, Trends & Forecasts (2018-2022)
Scope of the Report
The report entitled “China Cancer Drug Market: Size, Trends & Forecasts (2018-2022)”, provides analysis of the China cancer drug market, with detailed analysis of market size and growth, and value of the industry. The analysis includes the market by value, by cases and incidence ratio.
Moreover, the report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall China cancer drug market has also been forecasted for the years 2018-2022, taking into consideration the previous growth patterns, the growth drivers and the current and future trends.
Celgene, Novartis, Roche and Johnson & Johnson are some of the key players operating in the China cancer drug market, whose company profiling has been done in the report. In this segment of the report, business overview, financial overview and business strategies of the companies are provided.
Company Coverage
Cancer is a complex disease where uncontrolled growth of abnormal cells arises. Cancer is the process where new cell formation slows or start dividing, and form lumps. Cancer cells are different from normal cells. Cancer cells ignores signal of the body, evade the immune system and do not specialize in functioning.
There are various types of cancer in the world such as prostate cancer, lung & bronchus cancer, colon & rectum cancer, bladder cancer, breast cancer, kidney and renal pelvis cancer, thyroid cancer, endometrial cancer and others. For different cancer, different types of treatments are available in the market such as chemotherapy, surgery, radiation therapy, targeted therapies, immunotherapy, hormonal therapy, angiogenesis inhibitors and synthetic lethality.
There are different categories of anti-cancer drugs such as classic cytotoxic agents (alkylating agents, antimetabolites, and anti-microtubule agents, etc.), target-based anticancer drugs (selective or semi-selective), biologics or immunotherapy and hormones and hormone antagonists.
Chemotherapy is the most common cancer treatment. But there are few side-effects which are associated with chemotherapy treatment displaying different side effcets on different patients such as fatigue, hair loss, diarrhea, weight change, easy bruising and bleeding, nausea and vomiting, etc.
The China Cancer Drug Market is expected to increase at high growth rates during the forecasted period (2018-2022). The china cancer drug market is supported by various growth drivers, such as rising aging population, stress resulting in increasing cancer cases, introduction of cutting edge therapy, rising incidence ratio, etc. The market faces certain challenges, such as, cross-border consultation, failure of clinical trial, etc. few new market trends are also provided such as, accelerated approval for advanced cancer drugs, combination therapy, etc.
The report entitled “China Cancer Drug Market: Size, Trends & Forecasts (2018-2022)”, provides analysis of the China cancer drug market, with detailed analysis of market size and growth, and value of the industry. The analysis includes the market by value, by cases and incidence ratio.
Moreover, the report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall China cancer drug market has also been forecasted for the years 2018-2022, taking into consideration the previous growth patterns, the growth drivers and the current and future trends.
Celgene, Novartis, Roche and Johnson & Johnson are some of the key players operating in the China cancer drug market, whose company profiling has been done in the report. In this segment of the report, business overview, financial overview and business strategies of the companies are provided.
Company Coverage
- Celgene
- Novartis
- Roche
- Johnson & Johnson
Cancer is a complex disease where uncontrolled growth of abnormal cells arises. Cancer is the process where new cell formation slows or start dividing, and form lumps. Cancer cells are different from normal cells. Cancer cells ignores signal of the body, evade the immune system and do not specialize in functioning.
There are various types of cancer in the world such as prostate cancer, lung & bronchus cancer, colon & rectum cancer, bladder cancer, breast cancer, kidney and renal pelvis cancer, thyroid cancer, endometrial cancer and others. For different cancer, different types of treatments are available in the market such as chemotherapy, surgery, radiation therapy, targeted therapies, immunotherapy, hormonal therapy, angiogenesis inhibitors and synthetic lethality.
There are different categories of anti-cancer drugs such as classic cytotoxic agents (alkylating agents, antimetabolites, and anti-microtubule agents, etc.), target-based anticancer drugs (selective or semi-selective), biologics or immunotherapy and hormones and hormone antagonists.
Chemotherapy is the most common cancer treatment. But there are few side-effects which are associated with chemotherapy treatment displaying different side effcets on different patients such as fatigue, hair loss, diarrhea, weight change, easy bruising and bleeding, nausea and vomiting, etc.
The China Cancer Drug Market is expected to increase at high growth rates during the forecasted period (2018-2022). The china cancer drug market is supported by various growth drivers, such as rising aging population, stress resulting in increasing cancer cases, introduction of cutting edge therapy, rising incidence ratio, etc. The market faces certain challenges, such as, cross-border consultation, failure of clinical trial, etc. few new market trends are also provided such as, accelerated approval for advanced cancer drugs, combination therapy, etc.
1. EXECUTIVE SUMMARY
2. INTRODUCTION
2.1 Cancer: An Overview
2.1.1 Cancer: Meaning
2.1.2 Difference Between Normal and Cancer Cells
2.1.3 Types of Cancer
2.1.4 Treatments of Cancer
2.1.5 Classification of Anticancer Drugs
2.1.6 Side Effects of Chemotherapy
3. GLOBAL MARKET ANALYSIS
3.1 Global Cancer Drug Market: An Analysis
3.1.1 Global Cancer Drug Market by Value
3.1.2 Global Cancer Drug Market by Region (China and Rest of the World)
3.2 Global Cancer Drug Market: Product Analysis
3.2.1 Global PD-1 Market by Value
3.2.2 Global PD-1 Market by Type of Product
3.2.3 Global Zanubrutinib (Excluding China) Market by Value
4. CHINA MARKET ANALYSIS
4.1 China Cancer Drug Market: An Analysis
4.1.1 China Cancer Drug Market by Value
4.1.2 China Cancer Cases
4.1.3 Incidence of Types of Cancer of Cancer of China Out of the World
4.2 China Cancer Drug Market: Product Analysis
4.2.1 China PD-1 Market by Value
4.2.2 China Zanubrutinib Market by Value
5. MARKET DYNAMICS
5.1 Growth Drivrs
5.1.1 Rising Aging Population
5.1.2 Rising Incidence Ratio
5.1.3 Stress Resulting in Increasing Cancer Cases
5.1.4 Growing Urban Population
5.1.5 Increasing GNI Per Capita in China
5.1.6 Introduction of Cutting Edge Therapy
5.1.7 Changing Lifestyle and Rising Awareness
5.1.8 Public Medical Insurance
5.2 Challenges
5.2.1 Cross-Border Consultation
5.2.2 Failure of Clinical Trial
5.3 Market Trends
5.3.1 Accelerated Approval for Advanced Cancer Drugs
5.3.2 Combination Therapy
5.3.3 Exemption of Import Tariff on Cancer Drugs
6. COMPETITIVE LANDSCAPE
6.1 China Cancer Drug Market: Top Players Analysis
7. COMPANY PROFILING
7.1 Celgene
7.1.1 Business Overview
7.1.2 Financial Overview
7.1.3 Business Strategy
7.2 Novartis
7.2.1 Business Overview
7.2.2 Financial Overview
7.2.3 Business Strategy
7.3 Roche
7.3.1 Business Overview
7.3.2 Financial Overview
7.3.3 Business Strategy
7.4 Johnson & Johnson
7.4.1 Business Overview
7.4.2 Financial Overview
7.4.3 Business Strategy
2. INTRODUCTION
2.1 Cancer: An Overview
2.1.1 Cancer: Meaning
2.1.2 Difference Between Normal and Cancer Cells
2.1.3 Types of Cancer
2.1.4 Treatments of Cancer
2.1.5 Classification of Anticancer Drugs
2.1.6 Side Effects of Chemotherapy
3. GLOBAL MARKET ANALYSIS
3.1 Global Cancer Drug Market: An Analysis
3.1.1 Global Cancer Drug Market by Value
3.1.2 Global Cancer Drug Market by Region (China and Rest of the World)
3.2 Global Cancer Drug Market: Product Analysis
3.2.1 Global PD-1 Market by Value
3.2.2 Global PD-1 Market by Type of Product
3.2.3 Global Zanubrutinib (Excluding China) Market by Value
4. CHINA MARKET ANALYSIS
4.1 China Cancer Drug Market: An Analysis
4.1.1 China Cancer Drug Market by Value
4.1.2 China Cancer Cases
4.1.3 Incidence of Types of Cancer of Cancer of China Out of the World
4.2 China Cancer Drug Market: Product Analysis
4.2.1 China PD-1 Market by Value
4.2.2 China Zanubrutinib Market by Value
5. MARKET DYNAMICS
5.1 Growth Drivrs
5.1.1 Rising Aging Population
5.1.2 Rising Incidence Ratio
5.1.3 Stress Resulting in Increasing Cancer Cases
5.1.4 Growing Urban Population
5.1.5 Increasing GNI Per Capita in China
5.1.6 Introduction of Cutting Edge Therapy
5.1.7 Changing Lifestyle and Rising Awareness
5.1.8 Public Medical Insurance
5.2 Challenges
5.2.1 Cross-Border Consultation
5.2.2 Failure of Clinical Trial
5.3 Market Trends
5.3.1 Accelerated Approval for Advanced Cancer Drugs
5.3.2 Combination Therapy
5.3.3 Exemption of Import Tariff on Cancer Drugs
6. COMPETITIVE LANDSCAPE
6.1 China Cancer Drug Market: Top Players Analysis
7. COMPANY PROFILING
7.1 Celgene
7.1.1 Business Overview
7.1.2 Financial Overview
7.1.3 Business Strategy
7.2 Novartis
7.2.1 Business Overview
7.2.2 Financial Overview
7.2.3 Business Strategy
7.3 Roche
7.3.1 Business Overview
7.3.2 Financial Overview
7.3.3 Business Strategy
7.4 Johnson & Johnson
7.4.1 Business Overview
7.4.2 Financial Overview
7.4.3 Business Strategy
LIST OF FIGURES
Figure 1: Difference Between Normal and Cancer Cells
Figure 2: Types of Cancer
Figure 3: Different Treatments of Cancer
Figure 4: Classification of Anticancer Drugs
Figure 5: Side Effects of Chemotherapy
Figure 6: Global Cancer Drug Market by Value; 2015-2017 (US$ Billion)
Figure 7: Global Cancer Drug Market by Value; 2018-2022 (US$ Billion)
Figure 8: Global Cancer Drug Market by Region (China and Rest of the World); 2017 (Percentage, %)
Figure 9: Global PD-1 Market by Value; 2016-2017 (US$ Billion)
Figure 10: Global PD-1 Market by Value; 2018-2022 (US$ Billion)
Figure 11: Global PD-1 Market by Type of Product; 2016-2017 (US$ Billion)
Figure 12: Global Zanubrutinib (Excluding China) Market by Value; 2020-2022 (US$ Million)
Figure 13: China Cancer Drug Market by Value; 2011-2017 (US$ Billion)
Figure 14: China Cancer Drug Market by Value; 2018-2022 (US$ Billion)
Figure 15: China Cancer Cases; 2013-2017 (Million)
Figure 16: Incidence of Types of Cancer of China Out of the World ; 2015
Figure 17: China PD-1 Market by Value; 2020-2022 (US$ Billion)
Figure 18: China Zanubrutinib Market by Value; 2019-2022 (US$ Million)
Figure 19: China Population Above 65 years; 2011-2016 (Billion)
Figure 20: China Colorectal Cancer Trend; 2000-2030
Figure 21: Mortality-Incidence Ratio; 2016
Figure 22: Stress and Worry Penetration in Chinese Population; 2011-2016 (Percentage, %)
Figure 23: China Urban Population; 2011-2016 (Million)
Figure 24: China GNI Per Capita; 2011-2016 (US$)
Figure 25: Patients Access to New Oncology Drugs; 2011-2016 (Thousand)
Figure 26: Chinese Patients Cross-Border Consultation; 2016 (Percentage,%)
Figure 27: Celgene Revenue; 2013-2017 (US$ Billion)
Figure 28: Celgene Revenue by Product; 2017 (Percentage, %)
Figure 29: Celgene Revenue by Region; 2017 (Percentage, %)
Figure 30: Novartis Net Sales; 2013-2017 (US$ Billion)
Figure 31: Novartis Net Sales by Segment; 2017 (Percentage, %)
Figure 32: Novartis Net Sales by Region; 2017 (Percentage, %)
Figure 33: Roche Sales; 2013-2017 (US$ Billion)
Figure 34: Roche Sales by Segment; 2017 (Percentage, %)
Figure 35: Roche Sales by Region; 2017 (Percentage, %)
Figure 36: Johnson & Johnson Sales; 2013-2017 (US$ Billion)
Figure 37: Johnson & Johnson Sales by Segment; 2017 (Percentage, %)
Figure 38: Johnson & Johnson Sales by Region; 2017 (Percentage, %)
Figure 1: Difference Between Normal and Cancer Cells
Figure 2: Types of Cancer
Figure 3: Different Treatments of Cancer
Figure 4: Classification of Anticancer Drugs
Figure 5: Side Effects of Chemotherapy
Figure 6: Global Cancer Drug Market by Value; 2015-2017 (US$ Billion)
Figure 7: Global Cancer Drug Market by Value; 2018-2022 (US$ Billion)
Figure 8: Global Cancer Drug Market by Region (China and Rest of the World); 2017 (Percentage, %)
Figure 9: Global PD-1 Market by Value; 2016-2017 (US$ Billion)
Figure 10: Global PD-1 Market by Value; 2018-2022 (US$ Billion)
Figure 11: Global PD-1 Market by Type of Product; 2016-2017 (US$ Billion)
Figure 12: Global Zanubrutinib (Excluding China) Market by Value; 2020-2022 (US$ Million)
Figure 13: China Cancer Drug Market by Value; 2011-2017 (US$ Billion)
Figure 14: China Cancer Drug Market by Value; 2018-2022 (US$ Billion)
Figure 15: China Cancer Cases; 2013-2017 (Million)
Figure 16: Incidence of Types of Cancer of China Out of the World ; 2015
Figure 17: China PD-1 Market by Value; 2020-2022 (US$ Billion)
Figure 18: China Zanubrutinib Market by Value; 2019-2022 (US$ Million)
Figure 19: China Population Above 65 years; 2011-2016 (Billion)
Figure 20: China Colorectal Cancer Trend; 2000-2030
Figure 21: Mortality-Incidence Ratio; 2016
Figure 22: Stress and Worry Penetration in Chinese Population; 2011-2016 (Percentage, %)
Figure 23: China Urban Population; 2011-2016 (Million)
Figure 24: China GNI Per Capita; 2011-2016 (US$)
Figure 25: Patients Access to New Oncology Drugs; 2011-2016 (Thousand)
Figure 26: Chinese Patients Cross-Border Consultation; 2016 (Percentage,%)
Figure 27: Celgene Revenue; 2013-2017 (US$ Billion)
Figure 28: Celgene Revenue by Product; 2017 (Percentage, %)
Figure 29: Celgene Revenue by Region; 2017 (Percentage, %)
Figure 30: Novartis Net Sales; 2013-2017 (US$ Billion)
Figure 31: Novartis Net Sales by Segment; 2017 (Percentage, %)
Figure 32: Novartis Net Sales by Region; 2017 (Percentage, %)
Figure 33: Roche Sales; 2013-2017 (US$ Billion)
Figure 34: Roche Sales by Segment; 2017 (Percentage, %)
Figure 35: Roche Sales by Region; 2017 (Percentage, %)
Figure 36: Johnson & Johnson Sales; 2013-2017 (US$ Billion)
Figure 37: Johnson & Johnson Sales by Segment; 2017 (Percentage, %)
Figure 38: Johnson & Johnson Sales by Region; 2017 (Percentage, %)
LIST OF TABLES
Table 1: Types of Cutting Edge Treatments
Table 2: Cancer Drugs Approved from the Priority Review List; 2017
Table 3: Expected Sales of Combined Therapies in China; 2021-2025
Table 4: China Cancer Drug Market Player Comparison
Table 1: Types of Cutting Edge Treatments
Table 2: Cancer Drugs Approved from the Priority Review List; 2017
Table 3: Expected Sales of Combined Therapies in China; 2021-2025
Table 4: China Cancer Drug Market Player Comparison
